Hypertension in the Young Preventing the Evolution of Disease Versus Prevention of Clinical Events⁎⁎Editorials published in the Journal of American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology. by Williams, Bryan
H
P
V
B
L
T
w
t
t
w
t
“
d
t
i
e
r
a
o
r
i
s
b
i
d
t
B
t
i
t
e
t
w
r
T
t
c
v
t
r
T
r
O
a
t
U
p
l
p
u
h
i
t
i
B
s
s
r
c
s
r
s
t
i
“
l
i
b
c
B
r
d
s
h
B
b
a
o
e
m
v
T
c
*
o
C
M
r
p
d
Journal of the American College of Cardiology Vol. 50, No. 9, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2007.05.020EDITORIAL COMMENT
ypertension in the Young
reventing the Evolution of Disease
ersus Prevention of Clinical Events*
ryan Williams, MD, FRCP, FAHA
eicester, United Kingdom
wo great dilemmas in the treatment of hypertension are
hen to treat and how to assess the effectiveness of drug
herapy in younger patients. There is very little data about
he most effective treatment strategies for younger patients
ith high blood pressure (BP) (1,2). This is because clinical
rials are predicated on showing benefits of drug therapy on
hard clinical outcomes” such as stroke, coronary heart
isease, and mortality. To ensure sufficient end points over
he typical duration of clinical trials, the patients studied are
nvariably older and at high cardiovascular risk by virtue of
stablished complications. Indeed most trials have only
ecruited patients over age 50 years, and typically the mean
ge of patients in trials is 65 years or more. Moreover, most
f these older patients with established vascular damage
equire multiple drug therapies to control their BP, making
t difficult to isolate the potential benefit (or harm) of
pecific drug therapies, over and above the overwhelming
enefit of BP lowering per se in these older populations.
See page 835
It is conceivable that studies of earlier BP-lowering
ntervention in younger patients could yield a completely
ifferent perception of the effectiveness of specific drug
herapies, particularly with regard to both their efficacy at
P-lowering and, perhaps more importantly, their capacity
o prevent or regress structural damage.
Hypertension evolves over many years, and this leads to
mportant structural changes in small and large arteries and
he heart (3–7). Importantly, these structural changes begin
arly and often go undetected for many years. With regard
o small artery structure, there is a characteristic remodeling
hich results in thickening of the vascular media and a
Editorials published in the Journal of American College of Cardiology reflect the views
f the authors and do not necessarily represent the views of JACC or the American
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esearch grant support and honoraria for consultancy and lectures from a number ofh
harmaceutical companies involved in the manufacture of blood pressure-lowering
rugs.eduction in lumen size, increasing the wall/lumen ratio.
his change dramatically increases vascular resistance, set-
ing up a “pressure-damage-pressure” cycle of further in-
reases in BP and further vascular structural change (8).
With regard to large arteries, increased BP generates
ascular wall stress that contributes to progressive damage to
he elastic fibers and stiffening of the larger conduit arteries,
educing their compliance, which widens pulse pressure (5).
he consequence of large artery damage is the progressive
ise in systolic BP observed with aging in Western societies.
nce again, a perpetuating cycle ensues whereby the large
rtery damage results in further widening of pulse pressure
hat in turn increases wall stress, promoting further damage.
ltimately these changes disturb ventricular–vascular cou-
ling, increasing left ventricular wall stress and promoting
eft ventricular hypertrophy and dysfunction.
The aforementioned structural changes in hypertensive
atients are insidious and evolve over time. They usually go
ndetected in clinical practice until clinical signs of ischemic
eart disease, stroke, or renal disease develop, by which time
t is invariably too late to reverse the structural damage, and
reatment serves only to delay the further insidious decline
n end-organ function (6,7,9–13).
A key question is whether earlier intervention with
P-lowering therapy in younger patients would regress early
tructural damage and prevent further evolution of vascular
tructural changes? Such a finding could be important for 2
easons. First, intuition suggests that preventing cardiovas-
ular structural damage would most likely be beneficial. In
upport of this, recent studies have demonstrated that
egression of left ventricular hypertrophy is associated with
ubstantial improvements in survival (14). A second impor-
ant but poorly recognized rational for early therapeutic
ntervention is to prevent or break the aforementioned
pressure-damage-pressure” damage perpetuation cycle in
arge and small arteries. This damage cycle leads to an
nevitable progressive rise in of BP over time that ultimately
ecomes more resistant to treatment. There has been a
omplacent acceptance that the age-related rise in systolic
P and pulse pressure are inevitable—they are not, they
epresent the consequence of progressive vascular structural
amage. People are not born with drug-resistant hyperten-
ion! Could it be that much earlier treatment of the
ypertensive phenotype would arrest the relentless rise in
P that results in the use of multiple drug therapies in the
elated struggle to overcome the consequences of large
rtery damage on systolic pressure and small artery damage
n vascular resistance?
There is another important consideration in support of
arlier treatment of hypertension. There is a common
isconception that delayed treatment will completely re-
erse the risk associated with progressive structural damage.
he evidence from clinical trials suggests that this is
ertainly not the case and that most people with
ypertension-mediated vascular disease will eventually suc-
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August 28, 2007:840–2 Editorial Commentumb prematurely to its consequences. Delayed treatment
educes risk but never recovers the lost years.
In this issue of the Journal, Duprez et al. (15) report the
esults of an intriguing pilot study in which they have
valuated the capacity of BP-lowering with valsartan (an
ngiotensin receptor blocker [ARB]) to slow the progres-
ion of a range of early indicators of vascular disease in a
opulation of patients with hypertension (treated and un-
reated) whose BP is at goal (140/90 mm Hg). This study
et out to establish proof of principle that it would be
easible to detect early markers of benefit from therapeutic
ntervention. Various markers of early structural damage or
ysfunction were assigned an arbitrary score that was then
ggregated to yield a vascular disease score. This score was
eavily weighted toward structural abnormalities, which is
ppropriate, mindful of their importance. It should be
mphasized that the disease score has not been formally
alidated as a robust marker of clinical outcome, but it does
rovide a plausible and pragmatic index of early vascular
amage.
A weakness of the study is its small size and short
uration. The former led to inequalities in the baseline
cores between groups, and the latter might not have
llowed sufficient time for the structural benefits of inter-
ention to fully emerge. Nevertheless, it is worth recalling
hat this was a population of patients whose BP was
onsidered “controlled” according to current treatment
uidance. Treatment with the ARB reduced BP and the
ascular damage score by 6 months. The fact that this
enefit was also observed with the placebo-associated fall in
P suggests that the benefit was almost certainly driven by
he improved BP control, which was predictably better with
he ARB. However, the possibility of a specific additional
ffect of angiotensin receptor blockade to regress structural
bnormalities cannot be discounted. In support of the latter,
revious studies comparing an ARB (losartan) with a
eta-blocker (atenolol) have shown better structural regres-
ion and improved compliance of small arteries despite
imilar BP control after 1 year of treatment (16). This is
onsistent with an important role for the renin angiotensin
ystem as a mediator of early structural damage in younger
eople with a hypertensive phenotype.
It is of interest that the most impressive early benefit
eemed to be on the noninvasive assessment of small artery
ompliance, which is consistent with previous observations
uggesting that abnormalities in small artery structure and
unction might be the earliest manifestation of BP-
ediated damage (17). These findings complement those of
he TROPHY (Trial of Preventing Hypertension) study,
hich showed that treatment with an ARB (candesartan) in
eople with pre-hypertension might delay the development
f overt hypertension (18). No vascular structure data have
een reported from the TROPHY study. The TROPHY
tudy and that of Duprez et al. (15) are important, perhaps
ot so much by what they found but more by virtue of what
hey set out to study. They have challenged the boundariesf current therapeutic approaches to hypertension by high-
ighting the potential of earlier therapeutic intervention—
argeting the early evolution of disease and not just BP
alues. It is intriguing that both studies have used ARBs,
hich might ultimately turn out to be the most logical
ntervention in the context of early therapeutic intervention
n younger people, mindful of the importance of the
enin-angiotensin system (RAS) in the genesis of hyperten-
ion and structural damage in younger patients and the
eemingly innocuous adverse effect profile of ARBs.
The challenge for future studies will be to better define
linically important and meaningful markers of therapeutic
enefit on structural and functional cardiovascular damage.
his is a challenge that will be made easier by the exciting
evelopments in noninvasive imaging techniques to better
haracterize early damage. Moreover, the opportunities to
etter define differential drug effects on such markers will be
reater in patients treated with monotherapy with clearly
efined phenotypes. Indeed it is conceivable that in the early
tages of hypertension, structural regression could be more
ependent on properties of specific drug treatments and less
ependent on the BP-lowering efficacy. In this regard one
onders how many potentially novel therapeutic interven-
ions for early hypertensive disease have already been dis-
arded in early development, because they failed to over-
ome the crude BP criteria used to define a successful
reatment by the regulators.
In summary, for the treatment of hypertension, the
urrent focus is on preventing clinical end points. However,
or the insidious destructive process associated with an
levated BP, perhaps the focus would be better directed at
reventing the longer-term evolution of disease. Although
his strategy would increase the number of patients treated,
t could simplify and reduce the number of drugs used to
reat the majority of patients and ultimately improve their
onger-term outcome. For this radical change to occur, 2
ey things need to happen. First, future research and drug
evelopment strategies need to be focused on the means to
etter identify and treat those patients at risk of structural
amage. Second, there needs to be a radical change in the
rug regulatory environment to recognize the benefits of
pecific drug therapies on cardiovascular structural change
o that appropriate drugs can be licensed for this key
ndication. Without these developments we will continue to
truggle with the consequences of BP-mediated damage in
lder patients rather than more effectively dealing the cause.
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epartment of Cardiovascular Sciences, Clinical Sciences Build-
ng, Leicester Royal Infirmary, P.O. Box 65, Leicester, LE2 7LX
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